Omalizumab: a future innovation for treatment of severe ocular allergy?
Conjunctival and corneal manifestations of atopic keratoconjunctivitis (AKC) are chronic, disabling and may be blinding. In common with other allergic diseases, such as asthma and atopic dermatitis, AKC is characterised by an allergen-induced immune response mediated through expression of IgE. The humanised monoclonal IgE antibody Xolair (omalizumab) complexes with free circulating IgE, thereby preventing binding of IgE to FcepsilonRI receptors on immune cells. Omalizumab effectively alleviates the signs and symptoms of asthma. Given the pivotal role of IgE in the allergic cascade, it is hypothesised that omalizumab has potential as an entirely new therapeutic approach to AKC.
Williams
Patricia B
PB
Thomas R. Lee Centre for Ocular Pharmacology, Eastern Virginia Medical School, P.O. Box 1980, Norfolk, VA 23501, USA. pbwillia@umich.edu
Sheppard
John D
JD
D000368:Aged; D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy* / Q000276:immunology; D007637:Keratoconjunctivitis / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D000069444:Omalizumab
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab